Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | S100A9 | P06702 | 4/20 | 0.33 |
| ▸ | CCR4 | P51679 | 8/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25342803 | 0.84 | ERN1 (0.41) | PRKDCERN1S100A9CCR4LMNA | |
| SCHEMBL13674949 | 0.77 | GAA (0.33) | MAPT | |
| SCHEMBL2185520 | 0.75 | AKR1B1 (0.31) | PRKDCERN1 | |
| SCHEMBL28419440 | 0.72 | PIK3C3 (0.33) | S100A9CCR4 | |
| SCHEMBL20155268 | 0.72 | MAPT (0.36) | MAPTL3MBTL1CA12CA1CA2 | |
| SCHEMBL15718627 | 0.72 | S100A9 (0.31) | S100A9 | |
| SCHEMBL677174 | 0.71 | CCR4 (0.35) | S100A9CCR4LMNAALDH1A1HPGD | |
| SCHEMBL21634877 | 0.71 | GAA (0.32) | MAPTCA2 | |
| SCHEMBL31087530 | 0.69 | LMNA (0.41) | PRKDCERN1LMNAALDH1A1HPGD | |
| SCHEMBL22542733 | 0.69 | LMNA (0.41) | PRKDCERN1LMNAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267820-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED (IN) | 2022-03-08 | — | — | US | disclosed |
| EP-3347356-B1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2020-10-29 | — | — | US | disclosed |
| US-10689395-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | JUBILANT BIOSYS LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180237453-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2018-08-23 | — | — | US | disclosed |
| EP-3347356-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | Jubilant Biosys Limited (IN) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042834-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339595-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BRD2 | PRKDC 1388/4885ERN1 1827/4885S100A9 1731/4885 |
| US-20180237453-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | BRD4, BET1, BICRA | PRKDC 1207/4885ERN1 1966/4885S100A9 1855/4885 |
| US-10689395-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | BRD4, BET1, BICRA | PRKDC 1207/4885ERN1 1966/4885S100A9 1855/4885 |
| US-11267820-B2 | Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors | BRD4, BET1, BRD2 | PRKDC 1388/4885ERN1 1827/4885S100A9 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.